Insmed has been granted a patent for lipo-glycopeptide cleavable derivatives to treat bacterial infections, particularly in the lungs. The compounds are designed for faster clearance and cellular uptake. The method involves administering the compound via a nebulizer, dry powder inhaler, or metered dose inhaler. GlobalData’s report on Insmed gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Insmed, Peptide pharmacophores was a key innovation area identified from patents. Insmed's grant share as of February 2024 was 58%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of gram-positive pulmonary bacterial infections
A recently granted patent (Publication Number: US11857597B2) discloses a method for treating Gram-positive pulmonary bacterial infections in patients using a composition containing a specific compound or its salt. The method involves administering the composition via a nebulizer, dry powder inhaler (DPI), or metered dose inhaler (MDI). The patent specifies various types of Gram-positive pulmonary bacterial infections that can be treated using this method, including Staphylococcus, Enterococcus, and Streptococcus infections. Additionally, the method is particularly relevant for patients with cystic fibrosis.
The patent claims outline the specific details of the method, including the administration route, the types of infections targeted, and the patient population that can benefit from this treatment. By focusing on Gram-positive pulmonary bacterial infections, especially in cystic fibrosis patients, the method described in the patent offers a targeted approach to addressing these challenging medical conditions. The use of specific inhalation devices like dry powder inhalers further enhances the effectiveness and convenience of the treatment. Overall, this patent provides valuable insights into novel therapeutic strategies for combating Gram-positive pulmonary bacterial infections, particularly in vulnerable patient populations like those with cystic fibrosis.
To know more about GlobalData’s detailed insights on Insmed, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
